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Summary Selective delivery of cytotoxic anti-neoplastic drugs can diminish the severe side-effects associated
with these drugs. Many malignant tumours express high levels of low-density lipoprotein (LDL) receptors on
their membranes. Therefore, LDL may be used as a carrier to obtain selective delivery of anti-neoplastic drugs
to tumours. The present study was performed to investigate the feasibility of the murine B16 tumour/mouse
model for the evaluation of LDL-mediated tumour therapy. LDL binds with high affinity to LDL receptors on
cultured B16 cells (Kd, 5.9+2.3 Yg ml-; Bmax, 206+23 ng LDL mg-1 cell protein). After binding and
internalisation, LDL was very efficiently degraded: 724+ 19 ng LDL mg- cell protein h-'. Chloroquine and
ammonium chloride completely inhibited the degradation of LDL by the B16 cells, indicating involvement of
lysosomes. LDL receptors were down-regulated by 70% after preincubation of B16 cells with 300 jg ml-l
LDL, indicating that their expression is regulated by intracellular cholesterol. To evaluate the uptake of LDL
by the B16 tumour in vivo, tissue distribution studies were performed in C57/Bl mice inoculated with B16
tumours. For these experiments, LDL was radiolabelled with tyramine cellobiose, a non-degradable label,
which is retained in cells after uptake. At 24 h after injection of LDL, the liver, adrenals and the spleen were
found to be the major organs involved in LDL uptake, with tissue-serum (T/S) ratios of 0.82+0.08,
1.17+0.20 and 0.69+0.08 respectively. Of all the other tissues, the tumour showed the highest uptake of LDL
(T/S ratio of 0.40+0.07). A large part of the LDL uptake was receptor mediated, as the uptake ofmethylated
LDL was much lower. Although the LDL uptake by the liver, spleen and adrenals is higher than that by the
tumour, the LDL receptor-mediated uptake by these organs may be selectively down-regulated by methods that
do not affect the expression of LDL receptors on tumour cells. It is concluded that the B16 tumour-bearing
mouse constitutes a good model to evaluate the effectiveness of LDL-mediated delivery ofcytotoxic (pro)drugs
to tumours in vivo.
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The lack of selectivity of anti-neoplastic drugs is a major
problem associated with the chemotherapy of cancer. Often,
the toxicity of these drugs causes severe side-effects, which
preclude the administration of a fully effective dose for the
treatment of malignancies. Selective delivery of these
cytotoxic compounds to neoplastic cells would diminish the
unwanted side-effects and accomplish more effective drug
concentrations in the tumour. Several macromolecules and
particulate systems have been proposed as carriers for the
selective delivery of anti-tumour drugs. Among them are
monoclonal antibodies (Trail et al., 1993), liposomes (Fan et
al., 1990), microspheres, growth factors and hormones
(Tomlinson, 1987). An interesting endogenous carrier is
low-density lipoprotein (LDL), the predominant cholesterol-
transporting lipoprotein in man. LDL is a spherical particle
of about 23 nm, with a core of neutral lipids of mainly
cholesterol esters, and a shell consisting of a monolayer of
phospholipids and cholesterol. As a variety of lipophilic
compounds can be incorporated in the apolar core, LDL may
be used as a carrier for lipophilic drugs (Counsell and
Pohland, 1982, and reviewed by Firestone, 1994). A large
part of the surface of the particle is covered with apoprotein
B, which is recognised by specific LDL receptors on cells.
LDL is bound by the LDL receptor, internalised and
degraded in lysosomes. The released cholesterol is used for
the synthesis of cell membranes and, in some cell types,
steroid hormones and bile acids. In general, about 75% of
the uptake of LDL by cells is mediated by the LDL receptor
(Goldstein and Brown, 1977). The receptor-mediated uptake
of LDL is often determined by the cell's need for cholesterol.
Fast-growing cells, such as tumour cells, need large amounts
of cholesterol to synthesise new membranes. Indeed, results
from many studies indicate that a variety of tumour cells
have a higher expression of LDL receptors than the
corresponding normal cells (Firestone, 1994). Evidence for a
high expression of LDL receptors on tumour cells was
obtained by measuring binding and processing of LDL by
tumour cells in culture. Additional evidence came from
clinical studies in which a correlation was established between
increased clearance of LDL from the circulation and tumour
burden. Especially tumours of gynaecological origin and
myeloid leukaemic cells, but also colon, kidney, lung and
brain tumours, were found to express exceptionally high
amounts of LDL receptors (Firestone, 1994). The high
expression of LDL receptors on this variety of malignant
cells makes LDL an attractive carrier for receptor-mediated
delivery of anti-neoplastic drugs to tumours.
In a number of studies it was shown that lipophilic drug
molecules could be incorporated in LDL particles without
affecting the recognition of the particles by the LDL receptor.
Furthermore, killing of cultured tumour cells was achieved
with various drug-LDL complexes (Vitols et al., 1985;
Firestone et al., 1984; Tokui et al., 1994; Mosley et al., 1981;
Lundberg, 1993, Lestravel-Delattre et al., 1992). However, to
evaluate further the potential clinical application of LDL-
mediated selective drug delivery to tumours in vivo, it is
essential to develop an appropriate tumour-bearing animal
model. In a few earlier studies, the association of radio-
iodinated LDL with tumours was studied in tumour-bearing
mice (Norata et al., 1984; Lombardi et al., 1989; Hynds et al.,
1984). Lombardi et al. (1989) studied a panel of seven
tumours. They found that at 24 h after injection, the B16
melanoma tumour showed the highest tumour-liver ratio
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(approximately 2). However, the use of directly iodinated
LDL complicates the interpretation of the results, because the
obtained values (at 24 h circulation) reflect only the amount
of radiolabel present in the tissues at the time of sampling.
The amount of radiolabel that is excreted from cells after
degradation of the labelled LDL is not taken into account.
Consequently, the amount of radioactivity present in the
tumour and other tissues at the time of sampling does not
reflect the total amount of LDL taken up during the
experimental period. In the present study, loss of label from
tissues after degradation of LDL is precluded by the use of
tyramine cellobiose, a radiolabel that accumulates in cells
after internalisation and lysosomal processing (Pittman et al.,
1983). It has been demonstrated in a number of studies that
the radiolabelling with ['251]tyramine cellobiose does not
affect the recognition of LDL by the LDL receptor.
The aim of this study is to characterise further the
receptor-mediated interaction of LDL with B16 murine
melanoma cells. The expression of LDL receptors on the
tumour cells is measured. Further, the processing of LDL by
the cells is studied, as internalisation of drug-loaded LDL is
essential for an effective therapy. The receptor-mediated
uptake of LDL by the tumour in vivo is studied in B16
tumour-bearing mice. To provide an accurated determination
of the total amount of LDL taken up in vivo by the tumour
and non-tumour tissues, the LDL was labelled with
[1251]tyramine cellobiose, an intracellularly accumulating label.
Materials and methods
Chemicals
Sodium 1251, (carrier-free) was obtained from Amersham
International, Amersham, UK. Dulbecco's modified Eagle
medium (DMEM) was from Gibco BRL, Life Technologies,
Gaithersburg, MD, USA. Fetal calf serum (FCS) was
obtained from Hyclone Laboratories, Logan, UT, USA. L-
Glutamine was from Merck, Darmstadt, Germany. A
solution containing 50 000 IU penicillin and 50 mg ml-1
streptomycin was obtained from Boehringer Mannheim,
Mannheim, Germany. A solution of 2.5% (w/v) trypsin in
Hanks' balanced salt solution without Ca2+ and Mg2+ was
purchased from Flow Laboratories, Irvine, UK. All other
chemicals were of analytical grade.
Isolation of lipoproteins
Human LDL (density 1.024-1.063 g ml-1) and high-density
lipoprotein (HDL) (density 1.063-1.210 g ml-') were iso-
lated from the serum of healthy fasted volunteers by density
ultracentrifugation according to Redgrave et al. (1975). HDL
was subsequently depleted of apoprotein E-containing
particles, using a Sepharose-heparin column (Weisgraber
and Mahley, 1980). The LDL and HDL preparations were
dialysed against phosphate-buffered saline (PBS) (10 mM
sodium phosphate buffer, pH 7.4, containing 0.15 M sodium
chloride) and 1 mm EDTA, and sterilised by filtration
through a 0.22 ,gm filter (Millipore, Molsheim, France). The
concentration of the lipoprotein preparations was determined
by measuring their apoproteins, according to the method of
Lowry et al. (1951) with bovine serum albumin (BSA) as
standard.
Reductive methylation of LDL
LDL was reductively methylated as described by Weisgraber
et al. (1978). An aliquot of 1 ml of solution of LDL (3-4 mg
of apoprotein ml-') in 0.15 M sodium chloride containing
0.3 mM EDTA (pH 7.0) was mixed with 0.75 ml of 0.3 M
sodium tetraborate (pH 9.0). To this mixture, which was kept
on ice, were added 1 mg of sodium borohydride and 1 Ml of
formaldehyde. The reaction was allowed to react for a period
of 30 min, during which 1 pl of formaldehyde was added
every 6 min. The reaction was determined by separating, at
4°C, the methylated LDL from low molecular weight
reactants using a Sephadex G-25 column (0.8 x 25 cm) eluted
with 10 mM Tris-HCl containing 0.15 M sodium chloride
(pH 7.4). The methylated LDL (MeLDL) fraction was
subsequently dialysed at 4°C against PBS and 1 mM
EDTA. A minimum of 80% of the lysine residues were
modified by this procedure (determined as described by
Habeeb, 1966).
Radioiodination of LDL and MeLDL
For all in vitro experiments, LDL was labelled using the
[I25I]iodine monochloride method as described in detail by
Bilheimer et al. (1972). The specific radioactivity of 1251_
labelled (Me)LDL was 100-200 d.p.m. ng- of aproprotein,
and less than 1% of the labelled material was trichloroacetic
acid soluble.
For the in vivo experiments, MeLDL and LDL were
labelled with [1251]tyramine cellobiose (1251-TC). Synthesis
and subsequent radioiodination of TC was carried out as
described earlier by Pittman et al. (1983). Coupling of
['25I]TC to (Me)LDL was done as follows. To 50 pl of
0.3 mM [125I]TC were successively added 20 pl 0.75 mM
cyanuric chloride in acetone and 10 pl of 3.0 mM sodium
hydroxide. After 20 s, 20 M1 of 2.25 mM acetic acid was
added. The resulting activated ligand was added to 1-2 mg
of (Me)LDL in 1 ml of 20 mM sodium tetraborate buffer,
pH 9.0, that contained 0.12 M sodium chloride and 1 mM
EDTA. After 30 min at room temperature, the reaction was
quenched by the addition of an equal volume of 0.2 M
ammonium biocarbonate. Unbound label was removed by
exhaustive dialysis against PBS and 1 mM EDTA. Less
than 1% of the labelled material was trichloroacetic acid
soluble. The specific radioactivities of ['25I]TC-MeLDL and
[1251I]TC-LDL varied between 10 and 50 d.p.m. ng-'
aproprotein.
Culture of B16 melanoma cells
The B16 (wild-type) melanoma cell line was obtained from
Dr A Begg (The Netherlands Cancer Institute, Amsterdam,
The Netherlands). The cells were cultured at 37°C in a
humidified 5% carbon dioxide/air atmosphere in 125 cm2
flasks (Costar) containing 5 ml of DMEM supplemented with
10% (v/v) heat-inactivated FCS, 2 mM L-glutamine, 50 IU
penicillin ml-' and 50 pg ml-' streptomycin. Cells were
subcultured twice a week by detaching the cells with trypsin
(0.25% solution in Ca2+- and Mg2+-depleted Hanks' buffer),
followed by renewal of medium the following day. Protein
content per cell number was determined according to the
method of Lowry et al. (1951) with BSA as standard.
Binding, association and degradation of['25I]LDL by B16 cells
in culture
Cells were plated in 22 mm-diameter 12-well culture plates
at a density of approximately 10 000 cells per well.
Experiments were carried out 2 or 3 days later with
subconfluently grown cells. Before the cell experiments, the
culture medium was replaced by preincubation medium
(medium with 1% (w/v) BSA instread of FCS). The cells
were washed three times with preincubation medium (for 10,
10 and 30 min), and then cultured in this medium for a
further 18 h. Experiments were started, after two quick
washes with preincubation medium, by the addition of
preincubation medium containing the indicated amounts of
['251]LDL and the indicated additions.
Binding To determine binding of ['25I]LDL, the cells were
incubated with the radiolabelled ligand and the indicated
additives for 3 h at 4°C. After incubation, the culture plates
were placed on ice. The cells were washed five times with ice-
cold wash buffer (0.15 M sodium chloride, 2.5 mM calcium
chloride and 50 mM Tris-HCl, pH 7.4) containing 0.2% (w/v)Receptor-mediated uptake of LDL by B16 cells
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BSA, followed by two washes with the same buffer without
BSA. The cells were then lysed with 1 ml of 0.1 N sodium
hydroxide, and the amounts of protein and radioactivity in
the lysate were determined. The amount of cell protein was
determined by the method of Lowry et al. (1951) with BSA as
standard.
Association and degradation To determine association and
degradation of ['25I]LDL the cells were incubated with the
radiolabelled ligand and the indicated additives at 37°C.
After the incubation, the culture plates were placed on ice
and 0.5 ml of the medium was taken to measure the amounts
of released degradation products of ['25I]LDL according to
the method described earlier by van Berkel et al. (1981). The
cell-associated radioactivity was determined as described
above for cell-bound radioactivity.
Regulation of receptor expression For the experiments on
the LDL receptor regulation on B16 cells, the cells were, after
the initial 18 h of preincubation with preincubation medium
(1% BSA), incubated for another 24 h with preincubation
medium containing increasing amounts of LDL or HDL.
Then the cells were washed at 37°C (for 10, 10 and 30 min)
with preincubation medium without additions. The experi-
ments were started by adding preincubation medium
containing 10 jug ml-' ['251]LDL. After 3 h, the plates were
placed on ice and association and degradation were
determined as described above.
Tissue distribution of[I251]tyramine cellobiose-labelled LDL
and MeLDL in B16 tumour-bearing mice
Male C57/B16 mice (10-15 weeks old) were used. The
animals were kept on normal chow and had free access to
water. Mice were inoculated subcutaneously on their back
with 2 x 105 B16 cells obtained from cell culture. After
development of the tumour to a just palpable size, the mice
received an intravenous injection of radiolabelled LDL or
MeLDL in the tail vein (dose of approximately 40 jug of
apoprotein). In some experiments, mice were kept in
metabolic cages for the collection of urine and faeces.
Twenty-four h after the injection, a 0.4 ml blood sample
was taken and the mice were sacrificed. Organs were removed
by dissection, wiped with a tissue, weighed and the amount of
radioactivity was determined. The radioactivity measured in a
specific organ or tissue at the time of sampling was corrected
for the amount of serum radioactivity present in the tissue.
The amounts of serum in the organs and tissues were
determined in seperate experiments using [125I]BSA.
Results
Binding of LDL to B16 cells
To determine the number ofLDL receptors on B16 melanoma
cells and the affinity of the receptors for LDL, cells were
incubated at 4°C with increasing amounts of [125I]LDL. After
3 h ofincubation (i.e. atequilibrium conditions), the binding of
['25I]LDL to the cells was determined. Since receptors are not
internalised at4°C, only thebinding oftheligand to cell surface
receptors is measured. To determine aspecific binding of
[125I]LDL to the cells, an excess of unlabelled LDL was
added. The specific receptor-mediated binding of['25I]LDL was
calculated by subtracting the non-specific binding from the
total binding. From the results depicted in Figure 1, the
dissociation constant (Kd) ofthe specific binding ofLDL to B16
cells was calculated to be 5.9+2.3 Mg ml-1 [i.e. 11 nM,
assuming a molecular weight of 514 kDa for apoprotein B
(Knott et al.,. 1986)]. The maximal binding ofLDL to the cells
was found to be 206+23 ng of aproprotein per mg of cell
protein. Taking into account the protein content of the B16
cells, it can be calculated from this result that about 220 000
LDL receptors are expressed per cell.
Internalisation and catabolism of LDL by B16 cells
To investigate the internalisation and processing of LDL by
B16 cells, cells were incubated at 37°C for different time
periods with 10 Mg ml-' ['25I]LDL (Figure 2). A steady state
in internalisation and degradation became evident after
approximately 3-4 h. The maximal association was found
to be 816+50 ng of LDL mg-1 of cell protein. The rate of
degradation in the steady state was calculated to be
724+19 ng of LDL mg-' of cell proliferation h-'.
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Figure 1 Binding of [125I]LDL to B16 cells. B16 cells were
incubated at 4°C with the indicated amounts of [125I)LDL. After
3h of incubation, the total amount of cell-bound [125I]LDL was
determined (0). The aspecific binding of [125I]LDL to the cells
(0) was determined by including unlabelled LDL in the
incubations (500pgml-'). The receptor-specific binding (-- - -)
was calculated by subtracting the aspecific binding from the total
binding. Binding of [125I]LDL is expressed as ng of apoprotein
bound per mg of cell protein. Values are means+s.e.m. of four
separate experiments.
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Figure 2 Association and degradation of [125I]LDL by B16 cells.
B16 cells were incubated at 37°C with 10pgml-' [12 I]LDL. At
the indicated times, the amount of cell-associated radioactivity
(0) and the amounts ofdegradation products in the medium (0)
were determined. Values are means+s.e.m. of four separate
experiments.Receptor-mediated uptake of LDL by B16 cells
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The selectivity of the association and degradation was
investigated in a competition experiment (Figure 3). The cells
were incubated at 37°C with [125I]LDL in the presence of
increasing amounts of unlabelled LDL or methylated LDL.
Reductive methylation of only 20% or more of the lysine
residues on the apoprotein B molecule prevents the receptor
recognition of LDL, without changing other physical-
chemical parameters of the particle (Weisgraber et al.,
1978). The results presented in Figure 3 clearly indicate that
unlabelled LDL competes with [125I]LDL for binding to the
receptor. The cell association was decreased to less than 15%
of the control value by the addition of 200 jug ml-' of
unlabelled LDL. Methylated LDL, however, did not compete
with the iodinated LDL, even at high concentrations.
Chloroquine and ammonium chloride inhibit the lysoso-
mal degradation of internalised proteins by raising the pH
inside lysosomes (Seglen et al., 1979). Both compounds were
used to establish the involvement of the lysosomes in the
degradation of LDL by the B16 cells. The association of
['251]LDL by B16 cells was relatively unaffected by the
addition of the lysosomotropic compounds (Figure 4a).
However, the degradation of [125I]LDL could be completely
inhibited by these agents (Figure 4b), indicating that the LDL
is processed in B16 cells via the lysosomal route.
It has been shown earlier for a number of cell types that
the binding of LDL to its receptor is strictly Ca2" dependent
(Goldstein and Brown, 1977). Figure 5 shows that the
receptor-mediated association and degradation of [125I]LDL
by B16 cells is also Ca2+ dependent. Both association and
degradation were inhibited when the incubation medium was
virtually completely depleted of Ca2 . Only 0.2 mM Ca'+ was
sufficient to accomplish association and degradation of the
ligand.
Regulation of the expression of LDL receptors on B16 cells
To study the ability of the B16 cells to adapt to changes in
the supply of LDL, the regulation of the expression of the
LDL receptor on these cells was investigated. In these studies,
the cells were preincubated with increasing amounts of LDL.
After the preincubation period, the expression of LDL
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receptors on the cells was determined by measuring the
association and degradation of ['25I]LDL. The results from
this experiment, presented in Figure 6, clearly show that the
expression of LDL receptors on the B16 cells is subject to
regulation by LDL cholesterol. The preincubation with
300 ,ig ml-' of unlabelled LDL decreased the association
and degradation of LDL to 32% and 24% of the control
values respectively. Figure 6 also shows the effects of
preincubation with HDL (high-density lipoprotein). It can
be seen that preincubation with HDL does not decrease the
expression of LDL receptors on B16 cells, but may even
cause a slight increase.
Uptake of LDL in B16 tumour-bearing mice
To compare the uptake of LDL by B16 tumours with uptake
of LDL by non-maligant tissues, B16 tumour-bearing C57/
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Figure 3 Effects of unlabelled (Me)LDL on the association of [12 I]LDL by B16 cells. B16 cells were incubated at 370C with
lO,ugml- [ 25I]LDL in the presence of the indicated concentra-
tions of unlabelled native LDL (0) or MeLDL (A). After 3h of
incubation, the amount of cell-associated radioactivity was
measured. The association of [125I-]LDL is expressed as a
percentage of the control values obtained in the absence of
competitor. The 100% values for cell association were
2124+383ng of apoproteinmg-' of cell protein. Results are
means+s.e.m. of two separate experiments.
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Figure 4 Effects of chloroquine and ammonium chloride on the
association and degradation of [1251]LDL by B16 cells. B16 cells
were incubated at 37°C with 1Opgml - [125I]LDL in the presence
of 0.1 mm chloroquine (M), 10mM ammonium chloride (El), or
without additives (0). At the indicated times, the amount of cell-
associated radioactivity (a) and the amount of degradation
products in the medium (b) were determined. To compensate
for slow leakage ofNH4+ from lysosomes during the incubation,
ammonium chloride was added repeatedly every 30min. The data
represent the mean+s.e.m. of two seperate experiments.O Cell-associated
* Degraded
I_J
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Figure 5 Effects of Ca2+ on the association and degradation of
[12 I]LDL by B16 cells. B16 cells were incubated at 37'C with
lOgml- [125I]LDL. The Ca2+ concentration in the medium
(standard 1.8mM) was varied by the addition of extra calcium
chloride or by chelation with magnesium EGTA (to obtain
negative values for [Ca2+]). After 3h of incubation, the amount
of cell-associated radioactivity (0) and the amount of degrada-
tion products in the medium (M) were measured. Association and
degradation are expressed as percentages of the association and
degradation at 1.8mm Ca2 , which were 1674+238 and
1013+319ng apoprotein per mg of cell protein respectively.
Values are means+s.e.m. of three separate experiments.
B16 mice were intravenously injected with radiolabelled LDL.
Reductive methylation of LDL provides a well-established
tool for the determination of non-specific uptake of LDL
(Weisgraber et al., 1978; Mahley et al., 1980). Therefore, to
be able to distinguish between receptor-mediated and
aspecific uptake of LDL, tumour-bearing mice were also
injected with methylated LDL. In these experiments, LDL
and MeLDL were both labelled with 1251-TC, a label that is
retained in cells after uptake of its ligand (Pittman et al.,
1983). Tyramine cellobiose is an established radiolabel that is
widely used in studies on the in vivo metabolism of
lipoproteins. Pittman et al. (1983) showed, both in vivo, in
rats and in vitro with cultured human fibroblasts, that there is
no difference in recognition of 125I-TC-labelled LDL and
directly iodinated LDL by the LDL receptor. Therefore, the
in vitro results obtained with the directly iodinated LDL can
be directly correlated to the in vivo data obtained with TC-
labelled LDL.
At 24 h after injection of [251I]TC-LDL, 15+3% of the
injected dose was left in the plasma. [1251I]TC-MeLDL was
cleared more slowly: at 24 h after injection 23 +1% of the
dose was still in the plasma. The uptake of LDL and MeLDL
by the tumour and normal tissues, determined 24 h after
injection, is shown in Figure 7. Tissue -serum ratios are
expressed as the uptake of LDL per g of organ divided by the
amount of LDL per g of serum (density: 1.05 g ml-'). As has
been found earlier in other species (Dietschy et al., 1993),
adrenals, liver and spleen showed the highest tissue-serum
ratios after injection of [1251]TC-LDL, i.e. 1.17+0.2,
0.82+0.08 and 0.69+0.07 respectively. The observed uptake
by these tissues was largely receptor mediated, as is obvious
from the lower tissue-serum ratio of [125I]TC-MeLDL. The
relatively high amount of label in the intestines is probably
derived from the liver. It has been shown before in rats that
after uptake of [125I]TC-LDL by the liver part of the label is
excreted via the bile duct into the intestine (Kleinherenbrink-
Stins et al., 1990). The uptake of ['251I]TC-LDL by the tumour
was, with a tissue-serum ratio of 0.40+0.07, the highest of
all the other tissues.
The observed uptake of labelled LDL by the tumour was
approximately 2-fold lower than the hepatic uptake
(tumour-liver ratio of 0.48+0.06). This is in contrast with
the study by Lombardi et al. (1989), in which it was found
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Figure 6 Effects ofpreincubation of B16 cells with LDL or HDL
on the LDL receptor expression. B16 cells were preincubated at
37°C with the indicated amounts of unlabelled LDL (0) or HDL
(0). After 18h of preincubation, the cells were washed three
times (10, 10 and 30min between washes) at 37°C with medium
containing 1% BSA. This was followed by an incubation of the
cells with 10jugml-I [125lJLDL. After 3 h of incubation, the
amount of cell-associated [1 5I]LDL (a) and degradation products
in the medium (b) were measured. Data shown represent LDL
receptor-mediated association and degradation as they are
corrected for non-specific association/degradation (determined
by including 300 igml-l unlabelled LDL in the incubation).
The results are expressed as percentages of association and
degradation in controls (no lipoprotein present in the preincuba-
tion). Control values of association and degradation were
1120+68 and 231+9ng of apoprotein per mg of cell protein
respectively. The results are means+ s.e.m. of two different
experiments.
that uptake by the tumour was approximately two times
higher than the uptake by the liver. To investigate whether
the difference in results could be explained by the different
labels used (125I in the earlier study vs [125I]TC in this study),
we directly compared in B16 tumour-bearing mice the fate of
LDL-labelled with either label. At 24 h after injection, the
serum concentration [125I]LDL and [1251I]TC-LDL were very
similar: 11+2% and 15+3% of the dose respectively. The
observed tissue - serum ratios were, however, strikingly
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Figure 7 Tissue distribution of [125I]TC-LDL and [125I]TC-
MeLDL in mice inoculated with B16 cells. Male C57 black
mice, bearing a B16 melanoma, were injected with approximately
40jug of [125I]TC-LDL (0 ) or [125I]TC-MeLDL (_) in the tail
vein. After 24 h, a 0.4ml blood sample was taken and the mice
were sacrificed. Radioactivity was measured in the indicated
organs and tissues. For the determination of organ and tissue
uptake, the measured values were corrected for residual serum
present in the organ and tissue samples. Results are the
means + s.e.m. of three animals.
different (Figure 8). The amounts of label in tissues (in
particular in the high-uptake tissues liver, spleen and
adrenals) of mice injected with ['25I]LDL were much lower
than in mice injected with [125I]TC-LDL. These findings
indicate that in mice injected with ['25I]LDL the label is
rapidly procesed and excreted by the tissues. In mice injected
with [25I]LDL, the amount of label in the tumour was about
twice the amount of label in the liver, which is in good
agreement with the previously reported data.
Discussion
A variety of tumour cell types express high numbers of LDL
receptors, which makes LDL a very interesting carrier for the
selective delivery of drugs to these tumour cells. In this study,
we explored the feasibility of using the murine B16 melanoma
cell line for the evaluation of the effectiveness of LDL-
mediated tumour therapy. For this purpose, we characterised
the binding and processing of LDL by B16 cells in culture
and we studied the uptake of LDL by B16 tumours
inoculated in mice.
We found that B16 cells in culture specifically bind LDL
with high affinity (Kd = 5.9 jug ml-). Since the B16 cells
bound maximally 206 ng of LDL per mg cell protein, which
corresponds to approximately 220 000 LDL receptors per
cell, the affinity of binding of LDL to the B16 cells is very
similar to the affinity of binding of LDL to human
parenchymal cells (Kd =S ,g ml-1; Kamps et al., 1991).
However, the human parenchymal cells bound under similar
experimental conditions much less LDL (75 ,ug ml-' of cell
protein). The requirements for the interaction of LDL with
the receptors on the B16 cells are very similar to those of the
'classical' LDL receptors described by Brown and Goldstein,
(1977). The lysine residues of LDL were found to be essential
for the interaction with the receptor, as methylation of LDL
competely abolished the capacity of the particle to compete
for binding to the receptor. Further, the receptor-mediated
association and degradation of LDL were Ca2-dependent.
For an efficient intracellular delivery of drugs by an LDL
carrier, it is essential that the carrier is not only recognised,
but also activity internalised by the cells. B16 cells were
found to internalise and degrade LDL efficiently. The
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Figure 8 Tissue distribution of [1251]TC-LDL and [1251I]LDL in
mice inoculated with B16 cells. Male C57 black mice, bearing a
B16 melanoma, were injected with approximately 40jig of
[I1]TC-LDL (M) or [ 51]LDL (_) in the tail vein. After
24h, a 0.4ml blood sample was taken and the mice were
sacrificed. Radioactivity was measured in the indicated organs
and tissues. For the determination of organ and tissue uptake, the
measured values were corrected for residual serum present in the
organ and tissue samples. Results are means+ s.e.m. of three
animals for [125I]TC-LDL and two animals for [125I]LDL.
degradation of LDL by B16 cells could be completely
inhibited by the addition of chloroquine or ammonium
chloride to the culture medium. These findings indicate that
LDL is internalised by B16 cells and is subsequently degraded
in the lysosomes. Assuming a drug load of 100 molecules per
LDL particle, a cellular protein content of 15% and a
molecular weight of 514 kDa for apoprotein B, it can be
calculated from the rate constants in the steady state, that a
drug-LDL complex can deliver 21 ,umol of drug per litre of
cell volume per hour to the B16 cells. Since cytostatics, like
for instance anthracyclines, are effective at an intracellular
concentration in the jpM range (Speth et al., 1988), this clearly
allows the administration of an effective cytotoxic dose.
The expression of LDL receptors on non-malignant cells is
known to be regulated by the cells' need for cholesterol. We
found that in B16 cells the expression of LDL receptors is
also subject to regulation. Receptor-mediated association and
degradation of [125I]LDL were reduced by approximately
70% after preincubation with 300 jig ml-' LDL. Preincuba-
tion with HDL, a protein that extracts cholesterol from cells
(reverse cholesterol transport), did not decrease the level of
LDL receptor expression. In fact, a slight up-regulation of
the receptor was observed. A similar behaviour was found for
rat hepatocytes and HepG2 cells, a hepatoma cell line (Salter
et al., 1987; Havekes et al., 1986). In contrast, human
fibroblast cells were found to be more sensitive to receptor
regulation, since preincubation of fibroblasts with as little as
20 jug ml-1 of LDL led to a 75% decrease in LDL binding
(Brown and Goldstein, 1975), indicating a relatively
autonomic behaviour of the tumour compared with
fibroblasts.
To evaluate the uptake of LDL by the B16 tumour in vivo,
B16 cells were implanted in C57/BL6 mice and the tissue
distribution of intravenously injected [12"I]TC-LDL was
studied. In agreement with earlier studies on LDL
catabolism in vivo (Dietschy et al., 1993; Moerlein et al.,
1988), the liver (maintaining the cholesterol homeostasis), the
adrenals (production of steroid hormones), the spleen and the
intestinal tract were the major sites of recovery of LDL. The
lower uptake of [125I]TC-MeLDL by the liver, spleen and
adrenals indicates that the uptake of LDL by these organs is
mainly LDL receptor-mediated. The accumulation of LDL in
the intestinal tract after 24 h is probably a consequence of
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direct transport of a small part of the '25I-TC-labelled
apoprotein B from the liver via the bile to the gut, as was
reported earlier for 125I-TC-labelled LDL and asialofetuin
injected into rats (Pittman et al., 1983; Kleinherenbrink-Stins
et al., 1990). Of all other tissues, the tumour showed the
highest uptake of LDL, and the uptake by the B16 tumour
was mainly LDL receptor-mediated.
The observed ratio of uptake of ['25I]TC-LDL by the B16
tumour vs uptake by the liver was 0.48+0.06. In previous
studies, using [1251I]LDL, tumour-liver ratios of 1.5-2 were
found (Lombardi et al., 1989; Ponty et al., 1993). We show
here, by comparing directly the uptake of ['251I]TC-LDL and
[1251]LDL, that the difference between the present and earlier
studies is likely to be caused by the different labels used.
[125I]TC is an accumulating radiolabel, i.e. minimal loss of
label from the tissues occurs after internalisation and
degradation of ['251]TC-LDL. Degradation of internalised
[1251]LDL leads to a rapid loss of labelled degradation
products from the tissues. Consequently, the amounts of
label present in the tissue at the time of sampling are an
underestimation of the total amount of LDL taken up, in
particular if (as in the liver) the internalised [1251I]LDL is
rapidly degraded and excreted. Still, the recognition by the
LDL receptor is similar for both labels (Pittman et al., 1983).
It was found that for some reason, the 1251I label is retained
relatively longer in the tumour than in the liver resulting in
an overestimation (1.5-2 against 0.48) of the tumour-liver
ratio. It is thus clear that an accumulating radiolabel is
needed in order to determine accurately uptake of LDL by
(tumour) tissues. 99"Tc has also been used as an accumulating
radiolabel to follow the fate of LDL in B16 tumour-bearing
mice and other animals. However, 99-Tc does not accumulate
as well as [1251]TC (Ponty et al., 1993; Hay et al., 1991) and
the label is not sufficiently stable associated with LDL [25%
dissociation of label during 24 h of storage at room
temperature (Vallabhajosula et al., 1988)]. We therefore
conclude that our present values give the best possible
estimates of the activity of LDL receptor-mediated uptake of
tumour cells vs non-tumour tissues.
Uptake of LDL by the B16 tumour in the mouse thus
appears to be lower than uptake by the liver, spleen and
adrenals. If LDL is to be used as a carrier for delivery of
cytotoxic compounds to the tumour, precautions are
necessary to protect these organs from irreversible tissue
damage. Uptake by the liver can be decreased by a diet
enriched in cholesterol and triglycerides. The dietary fat is
delivered to the liver by chylomicron remnants, which are
taken up via liver-specific remnant receptors (van Dijk et al.,
1991). It has been shown in a number of studies that the high
influx of cholesterol and fatty acids results in a substantial,
up to 90%, down-regulation of hepatic LDL receptors
(Angelin et al., 1983). The expression of LDL receptors on
tumour cells, which lack remnant receptors, will be unaffected
by the diet. Further, the expression of LDL receptors in the
liver, but also in the spleen, can be down-regulated by the
administration of bile salts, like cholic acid or taurocholate.
Uptake of LDL by tumour cells was found to be unaffected
by the treatment (Hynds et al., 1984). The uptake of LDL by
the adrenals was shown to be greatly reduced in rats and
rabbits by the administration of corticosteroids like hydro-
cortisone or dexamethasone (Hynds et al., 1984; Isaacsohn et
al., 1986). Thus, it is possible specifically to down-regulate
LDL receptors on non-malignant cells, so that cytotoxic
compounds can be selectively delivered to tumour cells by an
LDL carrier.
In conclusion, we have shown that cultured murine B16
tumour cells bind and internalise LDL via specific LDL
receptors. The rate ofinternalisation of LDL was found to be
sufficiently high to allow a significant intracellular accumula-
tion of drugs incorporated in LDL carriers. B16 tumours
inoculated in mice take up substantial amounts of circulating
LDL via their LDL receptors. Liver, spleen and adrenals also
show a high uptake of LDL, but LDL receptors in these
organs can be specifically down-regulated, without affecting
the expression of LDL receptors on tumour cells. We
conclude that B16 tumour-bearing mice constitute a good
animal model to evaluate the feasibility of LDL-mediated
tumour targeting.
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